An immature B cell population from peripheral blood serves as surrogate marker for monitoring tumor angiogenesis and anti-angiogenic therapy in mouse models
- 29 May 2015
- journal article
- Published by Springer Nature in Angiogenesis
- Vol. 18 (3) , 327-345
Abstract
Tumor growth depends on the formation of new blood vessels (tumor angiogenesis) either from preexisting vessels or by the recruitment of bone marrow-derived cells. Despite encouraging results obtained with preclinical cancer models, the therapeutic targeting of tumor angiogenesis has thus far failed to deliver an enduring clinical response in cancer patients. One major obstacle for improving anti-angiogenic therapy is the lack of validated biomarkers, which allow patient stratification for suitable treatment and a rapid assessment of therapy response. Toward these goals, we have employed several mouse models of tumor angiogenesis to identify cell populations circulating in their blood that correlated with the extent of tumor angiogenesis and therapy response. Flow cytometry analyses of different combinations of cell surface markers that define subsets of bone marrow-derived cells were performed on peripheral blood mononuclear cells from tumor-bearing and healthy mice. We identified one cell population, CD45dimVEGFR1−CD31low, that was increased in levels during active tumor angiogenesis in a variety of transgenic and syngeneic transplantation mouse models of cancer. Treatment with various anti-angiogenic drugs did not affect CD45dimVEGFR1−CD31low cells in healthy mice, whereas in tumor-bearing mice, a consistent reduction in their levels was observed. Gene expression profiling of CD45dimVEGFR1−CD31low cells characterized these cells as an immature B cell population. These immature B cells were then directly validated as surrogate marker for tumor angiogenesis and of pharmacologic responses to anti-angiogenic therapies in various mouse models of cancer.Keywords
Funding Information
- Swiss Cancer League (CCRP OCS-01812-12-2005)
This publication has 76 references indexed in Scilit:
- Accessories to the Crime: Functions of Cells Recruited to the Tumor MicroenvironmentCancer Cell, 2012
- Elusive Identities and Overlapping Phenotypes of Proangiogenic Myeloid Cells in TumorsThe American Journal of Pathology, 2010
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor AngiogenesisCancer Cell, 2009
- Tumor AngiogenesisNew England Journal of Medicine, 2008
- Angiogenesis: an organizing principle for drug discovery?Nature Reviews Drug Discovery, 2007
- The multifaceted circulating endothelial cell in cancer: towards marker and target identificationNature Reviews Cancer, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989
- Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites FluidScience, 1983
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971